RAPP

BOSTON and SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological and psychiatric disorders, today announced that management will participate in two upcoming investor conferences. Stifel

BOSTON and SAN DIEGO, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced the closing of its previously announced separate underwritten public offerings

Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients

Rapport Therapeutics (RAPP) said Wednesday it priced separate offerings of $175 million of common s

Investing.com -- Rapport Therapeutics Inc (NASDAQ:RAPP) shares fell 20% in premarket trading Wednesday following the pricing of $350 million in combined stock and convertible note offerings.

US-listed premarket movers for Oct. 28, 2026, led by AUROW, BRAI, ELPW, RCT and AXGN among gainers, while SCKT, AXG, NEXR and GRMLW fell.

Gainers Pulmonx (NASDAQ:LUNG) stock increased by 33.1% to $2.63 during Wednesday's regular session. The company's market cap stands at $85.0 million. As per the press release, Q3 earnings came out yesterday.

Key TakeawaysRapport Therapeutics shares fell 22% today after it priced about $380 million of stock, pre-funded warrants, convertible notes and a private placement, with the shares sold at $21 each. Raising money a week after positive bipolar mania data is the right move for Rapport, even at a steep discount.